Posts

The Capital Efficiency Signal: When ROIC Stops Making Sense

In May 2026, two stories unfolded on opposite sides of the globe — and they asked the same question. In South Korea, HLB Innovation, a KOSDAQ-listed biotech company, issued ₩40.5 billion in zero-coupon convertible bonds, with the stated purpose of funding its subsidiary's CAR-T therapy clinical development pipeline. In the United States, Meta disclosed a 7% increase in AI capital expenditure for 2026, contributing to $700+ billion in projected Big Tech AI infrastructure spending. Investors did not celebrate Meta's announcement. They demanded evidence of return on invested capital. Two different markets. Two different scales. One identical underlying question: when a company deploys capital, is that capital actually working? What CEI Measures The Capital Efficiency Index is one of four leading indicators in the RaymondsIndex framework. It measures the alignment between capital deployment and value generation, tracking ROIC, asset turnover ratios, and investment deviation. A decl...
Post a Comment
Read more

This Week's Risk Radar: What RaymondsIndex Is Watching

This week, two stories from opposite sides of the world are pointing at the same structural problem: what happens when the people running companies make decisions that look like growth but function as preservation — of their own position, their own listing, their own seat at the table. The Korea Signal: When M&A Becomes a Survival Tool The Seoul Economic Daily reported this week that a wave of "defensive M&A" is sweeping Korea's KOSDAQ market. Listed small and mid-cap companies — facing dramatically tightened delisting thresholds set to take effect in July 2026 — are acquiring outside businesses not to create genuine value, but to hit the revenue and market cap numbers required to stay listed. The numbers are striking. One biotech firm acquired a pharmaceutical company and reported revenue growth of 135%. An education company acquired a tutoring brand and reported 248% revenue growth in one quarter. The acquisitions are real. The growth in the numbers is real. ...
Post a Comment
Read more

Decoding RaymondsIndex: Four Signals That Move Before the Balance Sheet Does

Introduction Two news items this week, from opposite sides of the Pacific, tell the same story. In Korea, Enchem — a KOSDAQ-listed battery materials company — has accumulated over 275 billion KRW in outstanding convertible bonds. The auditor has flagged going-concern uncertainty. The largest shareholder's shares were subject to forced selling (반대매매). The company was designated as an unfaithful disclosure entity. And yet: none of this is visible in a single-quarter income statement. The signals were structural, relational, and financial governance-based — long before the results showed up on paper. In the United States, activist investor Impactive Capital filed a proxy challenge against WEX Inc., arguing that the company's combined CEO/Chair structure and capital-allocation practices have driven sustained underperformance in ROIC and total shareholder return. Again: the issue is not a single bad quarter. It's a governance structure that insulates the wrong incentives. ...
Post a Comment
Read more

The Sacrifice Play: When One Company in a Portfolio Is Designed to Lose

In baseball, a sacrifice bunt is a strategic play. The batter gives up an out — deliberately — so another runner can advance. The team scores. The batter's statistics suffer. It is not failure. It is design. In corporate finance, the same logic applies. Not every company in a multi-asset portfolio is meant to generate returns for all stakeholders. Some are positioned to absorb losses, serve as debt warehouses, or fund exits for the controlling investor — while minority shareholders and institutional creditors absorb the downside. This is the sacrifice play. And Korea's Homeplus case is one of the most instructive recent examples. The Homeplus Timeline In 2015, MBK Partners — Korea's largest private equity firm — acquired Homeplus for approximately 7.2 trillion won, the largest PE deal in Korean history. Over the following decade, store assets were sold off in a series of sale-and-leaseback transactions, reportedly generating around 4 trillion won in proceeds. By Mar...
Post a Comment
Read more

What Individual Investors Don't See Until It's Too Late

On the morning of May 6, 2026, the U.S. Department of Justice and the Securities and Exchange Commission unveiled one of the most sweeping insider trading prosecutions in recent memory. Thirty individuals were criminally charged; 21 faced simultaneous civil enforcement by the SEC. At the center of the scheme: a Yale Law-trained mergers and acquisitions attorney who had worked at Sidley Austin, Latham & Watkins, and Goodwin Procter — three of the most prominent M&A practices in the world. From 2018 to 2024, he allegedly extracted material nonpublic information from nearly 30 pending corporate transactions. That information moved through a structured network — participants reportedly used code words like "Torahs" and "Mitzvahs" — whose members traded ahead of public announcements and split the profits. Individual investors, reading the same press releases hours or days later, absorbed the other side of those trades. The Architecture of Information Asymmetry ...
Post a Comment
Read more

The Zombie Pattern: How Distressed Companies Drain Before They Fall

In December 2025, the Bank of Japan raised its policy rate from 0.50% to 0.75%. The number looks small. The implication is not. After three decades during which money cost nothing, an estimated 210,000 zombie companies in Japan are being repriced in real time. Corporate bankruptcies crossed 10,000 cases in 2025 , the highest in 12 years. A new law expected to take effect in 2026, the Early Business Revitalization Act, will allow majority-vote private restructuring — a deliberate signal that the state no longer wants every distressed firm kept alive. Korea is on the same curve, on a different timeline. The Korea Exchange has confirmed 42 KOSDAQ companies are at delisting risk this cycle , up 4 from a year ago. Eleven of them — including Samyoung E&C, Jeil M&S, COSNINE, TOBESOFT, EOFLOW and Korea United Pharm — have now received two consecutive years of auditor disclaimers. Eight more, after three years, are already past decision and in suspended liquidation. KRX has compress...
Post a Comment
Read more

Follow the Cash: When Raised Capital Doesn't Move

 In April and May 2026, Korean biotech companies collectively issued more than 1.1 trillion won — approximately $807 million — in zero-coupon convertible bonds. The structure is simple: no interest, no maturity coupon, just a bet on share-price upside embedded in the conversion option. D&D Pharmatec alone raised 226.5 billion won ($166 million) in a single deal, the largest CB transaction in the Korean biotech sector this year (Seoul Economic Daily, 2026.05.03). For issuing companies, the logic is compelling. Capital arrives with no cash-outflow burden. The balance sheet swells. Optically, the company looks well-funded. But the question that matters to individual investors is not how much was raised. It's where the money went. The CGI Signal RaymondsIndex tracks this question through the Cash Governance Index (CGI) — one of four leading indicators that measure the structural health of a company's relationship with its own capital. CGI specifically monitors three patterns: t...
Post a Comment
Read more